New IBCG consensus: Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group (IBCG) Full text: authors.elsevier.com/a/1mf5C… @shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

🔬✨ Discover the surgical innovations reshaping bladder cancer care on a new Global Perspectives webinar on SIU Academy! Join top global experts for this informative session on cutting-edge resection techniques, robotic & open radical cystectomy, and real-world strategies to improve outcomes in MIBC. Watch open access on SIU Academy: bit.ly/3Z3sInF @fkorkes @jteoh_hk @UroMoschini @SimonemorraMD

What a lovely memento of the #BLADDR25 family. Looking forward to #BLADDR26 in #Amsterdam - come & join us - Dec 2-5 2026! @mirrorsmed @issecam #PROSCA25 #RENALC25

Join us for an interactive seminar on 'Shaping the future: advancing HR-NMIBC management beyond BCG' live from #EMUC25. Register for free here 👉 ecancer.org/EMUC #bladder #urology #Oncology @LAUrology_NL @UroMoschini @evanguelosx

Fantastic #bladdercancer session at #EMUC2025 with a brilliant discussion and a truly stellar panel. So much is chanhing with new treatments, and urologists need to be ready for what’s coming next. @Uroweb

🤩Happy to be part of this timely collaborative multicenter review 🧪The role of ICIs in #NMIBC 📰Just published in @Cancers_MDPI @MDPIOpenAccess 👓Read it: t.ly/gYKQp ✍️@evanguelosx @BenjaminPradere @UroMoschini among others

📢 New SOC for MIBC #ESMO25 Dr. Christof Vulsteke presents KEYNOTE-905: 🚫 No cisplatin? No problem. EV pembro delivers. 👥 n=344 cis-ineligible MIBC (80% renal impairment, 15% ECOG 2) 🔹 EFS HR 0.40 | OS HR 0.50 🔹 pCR: 57.1% vs 8.6% (ITT, non-op = non-responders) 🔹 No ↑ surgical complications ✅ 1st phase 3 trial showing OS benefit in this population| Unprecedented pCR↑ @urotoday @myESMO

In anticipation of #esmo2025 please find a perfect summary of #bladdercancer trials made by our @UroOnc fellow superstar @hjwang26 .. looking forward to 📊🧑‍💻 ALBAN, POTOMAC @IBCG_BladderCA @CleClinicUro ..

Explore the current definitions, treatment paradigms, & clinical dilemmas of NMIBC in this new #UROwebinar! The experts will address optimal risk stratification, tx duration, & future therapeutic directions. Register here 👇 webinars.uroweb.org/EAU/webi… @LAUrology_NL @UroMoschini

The Urothelial Cancer Update 2025 is officially underway. Esteemed experts are on stage sharing the latest advancements in diagnosis and treatment. ​What has been the most impactful session for you so far? Let us know in the comments! 👇 @cittasalute_to @unito @UroMolinette

Agree with @shilpaonc amazing growth of @IBCG_BladderCA with global mission bringing experts together to develop guidelines based on evidence & consensus! @UrogerliMD @UroMoschini @spsutkaMD @MaxKates @siadaneshmand @shilpaonc @SpiessPhilippe @WesKassouf @AndreaNecchi @UroDocAsh

Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25! Together we’ll focus on two crucial goals: integrating bladder cancer biomarkers into clinical practice, and developing tools to better monitor and address local bladder toxicity - guided by the patient voice. Both topics reflect our @IBCG_BladderCA mission: to create real-world solutions that improve outcomes and provide practical tools for patients worldwide; through collaboration, collaboration and ... more collaboration! @shilpaonc @UrogerliMD @pjhensley11 @BladderCancerUS @WorldBladderCan @AndreaNecchi @PGrivasMDPhD @siadaneshmand @bbmdmsk @MaxKates @VigneshPackiam @LauraBukavinaMD @drtanws @niyatilobo @MarekBabjuk @joanfundi @RobertoContieri @mouwlab @OAlhalabiMD @urotoday @WesKassouf @SimaPorten @UroMoschini @LAUrology_NL @AStenzl @Agarwal_CaB @marigfern @spsutkaMD @jteoh_hk @Heer_Lab @SpiessPhilippe @SWilliams_MD @achoud72 @paolo_gontero @JanetKukreja @BenjaminPradere @GustavoVillold4 @TomFlaigMD @DrByronLee @KKBree @gautiermarcq @LiangChengMD @h_alahmadie @djmcconkey @BogdanaSchmidt @bkonety

Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday > bit.ly/43A7qRH

A honor to present the latest updates on urinary #biomarkers in HG NMIBC follow-up at the @Uroweb #uroonco congress. Have you read the DaBlaCa-15 Trial paper published in @EUplatinum? Check that out Thanks inviting me @foxal72 @UroMoschini and to my opponent @evanguelosx 🙏🏻

A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol authors.elsevier.com/c/1l7pU… There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday > bit.ly/43A7qRH

Complete vs partial TURBT for muscle-invasive #BladderCancer treatment. @UroLiedberg, @UroMoschini & @BenjaminPradere join @UroDocAsh in a discussion on the extent of transurethral resection of bladder tumor needed in #MIBC. They debate the value of complete resection when considering bladder-sparing approaches, neoadjuvant therapy, and clinical trials. #WatchNow on UroToday > bit.ly/42nD3NM

Review – Bladder Cancer: The Financial Burden of Localized and Metastatic Bladder Cancer by Pietro Scilipoti, @UroMoschini et al Read the full article here: buff.ly/44pcBYA #UroSoMe #MedTwitter #EurUrol #BladderCancer

Risk stratification for active surveillance in low and intermediate-risk #BladderCancer. @UroMoschini @SanRaffaeleMI and @UroDocAsh @MDAndersonNews discuss expanding active surveillance criteria for recurrent low-grade bladder cancer. #WatchNow > bit.ly/42wshVz

Complete vs partial TURBT for muscle-invasive #BladderCancer treatment. @UroLiedberg, @UroMoschini & @BenjaminPradere join @UroDocAsh in a discussion on the extent of transurethral resection of bladder tumor needed in #MIBC. They debate the value of complete resection when considering bladder-sparing approaches, neoadjuvant therapy, and clinical trials. #WatchNow on UroToday > bit.ly/42nD3NM